GlobalData on MSN21h
BMJ’s Phase III Opdualag study fails to meet endpoints
The combination therapy failed to beat out the company’s other cancer therapy, Opdivo, in patients living with melanomas.
pharmaphorum22h
BMS study of Opdualag in adjuvant melanoma ends in failure
Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab ...
The Pharma Letter18h
Bristol Myers’ Phase III Opdualag trial misses goal
Bristol Myers Squibb today announced the Phase III RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) ...
BioSpace21h
BMS’ Phase III Opdualag Melanoma Fail Could Limit Market Opportunity: Analysts
The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts.
Fierce Pharma22h
Bristol Myers Squibb comes up short in bid to expand Opdualag in melanoma
Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...
Endpoints News20h
Bris­tol My­ers’ Op­du­alag stum­bles in late-stage re­sect­ed melanoma tri­al
Bristol Myers Squibb's Opdualag (relatlimab/Opdivo) fails Phase 3 melanoma trial, adding to mixed results for LAG-3/PD-1 ...
Moderna’s Shot Sales, Canceled Contract Lead to Another Loss
Moderna Inc. recorded a quarterly loss as vaccine sales waned and the company had an unexpected charge for a canceled ...
MPR17h
Nivolumab/Relatlimab Combo Fails to Meet RFS Endpoint in Melanoma Trial
Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 blocking antibody, and relatlimab, a lymphocyte activation gene 3 blocking antibody.